Recent Advances in Drug Targeting for Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 6946
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer remains the leading cause of death despite the tremendous effort in the development process of active ingredients and therapeutic approaches and delivery strategies. This hurdle may account for the resistance and metastatic progression due to the lack of specificity of active treatments. The targeting therapy sheds light for a better hope of “cure” in which cell–cell communication, cellular surface, cellular organelle, intrinsic signaling or cellular genetic materials could be on target for a potential treatment. This Special Issue proposes an open forum for updated strategies towards target cancer cells. New molecules, therapies with a low cytotoxicity, high efficacy or delivery systems with high loading capacity, biocompatibility, and tumor specificity could offer cancer patients new opportunities for improving effectiveness and life quality.
We look forward to receiving your contributions.
Dr. Hiep Tuan Tran
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncology
- nanotechnology
- gene therapy
- targeting therapy
- anticancer drugs
- drug delivery systems
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.